Biotech entity
All 1 tracked stories fall under one category: gene-therapy. Bluebird Bio is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 20 original sources on average. We currently track 1 Biotech story that mention Lyfgenia, all published on July 9, 2026.
Last mentioned: Jul 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: gene-therapy. Bluebird Bio is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 20 original sources on average. We currently track 1 Biotech story that mention Lyfgenia, all published on July 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lyfgenia. Shared-story counts are live from our verified record — not editorial picks.
The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Source: wdov.iheart.com · kogo.iheart.com
Lyfgenia is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
